Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
12
Expiration
Dec 11, 2026
DTE
28d
Moneyness
OTM
Intrinsic
$0.00
IBRX 12 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.15 | -70.59% | 1 | 214 |
| Nov 20, 2026 | 7d | $0.10 | -28.57% | 41 | 8,364 |
| Nov 27, 2026 | 14d | $0.35 | +0.00% | 13 | 18 |
| Dec 4, 2026 | 21d | $0.36 | -26.53% | 3 | 244 |
| Dec 11, 2026 | 28d | $0.45 | +0.00% | 3 | 3 |
| Dec 18, 2026 | 35d | $0.40 | -16.67% | 13 | 302 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $0.60 | -20.00% | 16 | 9,906 |
| Mar 19, 2027 | 126d | $1.00 | +11.11% | 54 | 404 |
| Apr 16, 2027 | 154d | $1.20 | -4.00% | 32 | 209 |
| May 21, 2027 | 189d | $1.00 | -5.66% | 1 | 209 |
| Aug 20, 2027 | 280d | $2.00 | -10.31% | 5 | 52 |
| Nov 19, 2027 | 371d | $2.50 | +8.70% | 1 | 20 |
| Jan 21, 2028 | 434d | $2.24 | +4.67% | 5 | 1,702 |
| Mar 17, 2028 | 490d | $4.01 | +14.57% | 4 | 219 |
| Jan 19, 2029 | 798d | $4.00 | +14.29% | 7 | 38 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.